INmune Bio (NASDAQ:INMB) is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.
The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions. XPro1595 is currently being evaluated in early-stage clinical trials for indications including Alzheimer’s disease and various solid tumors. Complementing this, INmune Bio is developing NB-01, an innate immune activator aimed at stimulating gamma-delta T cells through toll-like receptor 2 (TLR2) agonism, with potential applications in oncology and infectious diseases.
Founded in 2014 by a team of immunology and biotechnology veterans, INmune Bio advanced to a public listing on the NASDAQ market in 2018. The company supports a diverse pipeline spanning preclinical and Phase 1 studies, leveraging collaborations with academic institutions and clinical research organizations. While headquartered in the United States, INmune Bio’s programs involve clinical sites across North America, reflecting its commitment to addressing global therapeutic needs.
The leadership team comprises professionals with extensive experience in drug discovery, clinical development and commercial strategy within the biopharmaceutical industry. Under their guidance, the company continues to expand its platform capabilities, seeking to translate innate immune modulation into novel treatments for patients with limited options.
